We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Read MoreHide Full Article
In the latest close session, Novo Nordisk (NVO - Free Report) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%.
The drugmaker's shares have seen an increase of 4.13% over the last month, not keeping up with the Medical sector's gain of 5.8% and outstripping the S&P 500's gain of 0.25%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. In that report, analysts expect Novo Nordisk to post earnings of $0.82 per share. This would mark a year-over-year decline of 15.46%. At the same time, our most recent consensus estimate is projecting a revenue of $11.27 billion, reflecting a 3.58% fall from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.39 per share and revenue of $44.61 billion. These totals would mark changes of -14.39% and -4.63%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.99% decrease. At present, Novo Nordisk boasts a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 14.59. For comparison, its industry has an average Forward P/E of 16.35, which means Novo Nordisk is trading at a discount to the group.
Investors should also note that NVO has a PEG ratio of 4.5 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 230, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
In the latest close session, Novo Nordisk (NVO - Free Report) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%.
The drugmaker's shares have seen an increase of 4.13% over the last month, not keeping up with the Medical sector's gain of 5.8% and outstripping the S&P 500's gain of 0.25%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. In that report, analysts expect Novo Nordisk to post earnings of $0.82 per share. This would mark a year-over-year decline of 15.46%. At the same time, our most recent consensus estimate is projecting a revenue of $11.27 billion, reflecting a 3.58% fall from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.39 per share and revenue of $44.61 billion. These totals would mark changes of -14.39% and -4.63%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.99% decrease. At present, Novo Nordisk boasts a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 14.59. For comparison, its industry has an average Forward P/E of 16.35, which means Novo Nordisk is trading at a discount to the group.
Investors should also note that NVO has a PEG ratio of 4.5 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 230, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.